Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights PART 05: An overview of PAH PART 06: Pipeline analysis PART 07: Market landscape • Market overview • Five forces analysis PART 08: Market segmentation by route of administration (RoA) • Oral administration • Injectables • Inhalation PART 09: Market segmentation by mechanism of action (MoA) • ERAs • Prostacyclin analogs • PDE inhibitors • sGC stimulators PART 10: Geographical segmentation • PAH market in Americas • PAH market in EMEA • PAH market in APAC PART 11: Decision framework PART 12: Drivers and challenges • Market drivers • Impact of drivers on key customer segments • Market challenges • Impact of challenges on key customer segments PART 13: Market trends • Increased focus on combination therapies • Increase in awareness • Intense competition among vendors PART 14: Vendor landscape • Competitive scenario PART 15: Key vendor analysis • Actelion Pharmaceuticals • DAIICHI SANKYO • GlaxoSmithKline • Novartis • United Therapeutics • Other prominent vendors PART 16: Appendix • List of abbreviations List of Exhibits Exhibit 01: Categorization of PAH Exhibit 02: Pipeline overview Exhibit 03: Pipeline landscape Exhibit 04: Global PAH drugs market snapshot Exhibit 05: Global PAH drugs market 2016-2021 ($ millions) Exhibit 06: Opportunity analysis of global PAH market 2016 Exhibit 07: Five forces analysis Exhibit 08: Market segmentation by RoA Exhibit 09: Global PAH drugs market segmentation by RoA 2016 Exhibit 10: Global PAH drugs market segmentation by MoA Exhibit 11: Global ERAs market 2016-2021 ($ millions) Exhibit 12: Global prostacyclin analogs market 2016-2021 ($ millions) Exhibit 13: Global PDE inhibitors market 2016-2021 ($ millions) Exhibit 14: Global PAH sGC stimulators market 2016-2021 ($ million) Exhibit 15: Geographical segmentation of PAH drugs market Exhibit 16: PAH drugs market revenue by geography 2016-2021 (%) Exhibit 17: Market scenario in Americas Exhibit 18: PAH drugs market in Americas 2016-2021 ($ millions) Exhibit 19: Market scenario in EMEA Exhibit 20: PAH drugs market in EMEA 2016-2021 ($ millions) Exhibit 21: Market scenario in APAC Exhibit 22: PAH drugs market in APAC 2016-2021 ($ millions) Exhibit 23: Impact of drivers Exhibit 24: Impact of challenges Exhibit 25: Competitive structure analysis of global PAH drugs market 2016 Exhibit 26: Competitive analysis of global PAH drugs market 2016 Exhibit 27: Actelion Pharmaceuticals: Key highlights Exhibit 28: Actelion Pharmaceuticals: Strength assessment Exhibit 29: Actelion Pharmaceuticals: Strategy assessment Exhibit 30: Actelion Pharmaceuticals: Opportunity assessment Exhibit 31: DAIICHI SANKYO: Key highlights Exhibit 32: DAIICHI SANKYO: Strength assessment Exhibit 33: DAIICHI SANKYO: Strategy assessment Exhibit 34: DAIICHI SANKYO: Opportunity assessment Exhibit 35: GlaxoSmithKline: Key highlights Exhibit 36: GlaxoSmithKline: Strength assessment Exhibit 37: GlaxoSmithKline: Strategy assessment Exhibit 38: GlaxoSmithKline: Opportunity assessment Exhibit 39: Novartis: Key highlights Exhibit 40: Novartis: Strength assessment Exhibit 41: Novartis: Strategy assessment Exhibit 42: Novartis: Opportunity assessment Exhibit 43: United Therapeutics: Key highlights Exhibit 44: United Therapeutics: Strength assessment Exhibit 45: United Therapeutics: Strategy assessment Exhibit 46: United Therapeutics: Opportunity assessment

Actelion Pharmaceuticals, DAIICHI SANKYO, GlaxoSmithKline, Novartis, United Therapeutics, AADi, Actelion Pharmaceuticals, Aires Pharmaceuticals, Arena Pharmaceuticals, Asklepion Pharmaceuticals, AstraZeneca, Bayer Healthcare, Berlin Cures, BIAL, DEKA Research & Development, Dong- A ST, Eiger BioPharmaceuticals, Gilead Sciences, Lung Biotechnology, Merck, Northern Therapeutics, Pfizer, PhaseBio Pharmaceuticals, Radikal Therapeutics, Reata Pharmaceuticals, SteadyMed Therapeutics, and Velo Bio.